Skip to main
BHVN
BHVN logo

BHVN Stock Forecast & Price Target

BHVN Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 40%
Buy 48%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Biohaven Ltd focuses on advanced therapies across significant therapeutic areas such as immunology, neuroscience, and oncology, with promising financial projections anticipated for its pipeline, including expected sales growth from $18 million in 2025 to $299 million in 2026, potentially reaching a peak of $1.15 billion. The company is gaining confidence in its IgG degrader platform, demonstrating 80% median IgG reduction in four weeks, which is indicative of meaningful clinical activity and enhances its product development outlook. Furthermore, Biohaven benefits from a strong management team with a track record of successful product launches and strategic insights drawn from competitors, positioning the company favorably within a supportive market landscape.

Bears say

Biohaven Ltd faces significant risks that contribute to a negative outlook, primarily stemming from the potential failure of pivotal Phase III readouts and setbacks in the Kv7 program, which could adversely impact the company's estimates and valuations. Additionally, the firm faces multiple operational challenges, including the emergence of unexpected safety signals, insufficient clinical efficacy, and difficulties in commercialization within a competitive landscape. Furthermore, the company's substantial expenditures in research and development (R&D) and selling, general, and administrative (SG&A) expenses may hinder its ability to finance ongoing operations, raising concerns about long-term sustainability.

BHVN has been analyzed by 25 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 48% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biohaven Pharmaceutical Hld and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biohaven Pharmaceutical Hld (BHVN) Forecast

Analysts have given BHVN a Buy based on their latest research and market trends.

According to 25 analysts, BHVN has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biohaven Pharmaceutical Hld (BHVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.